Compare HBM & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBM | ICLR |
|---|---|---|
| Founded | 1927 | 1990 |
| Country | Canada | Ireland |
| Employees | 3072 | N/A |
| Industry | Metal Mining | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.3B |
| IPO Year | 2005 | 2001 |
| Metric | HBM | ICLR |
|---|---|---|
| Price | $25.08 | $124.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $25.00 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 4.5M | 1.4M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $14.54 | N/A |
| P/E Ratio | $21.47 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.04 | $66.57 |
| 52 Week High | $28.74 | $211.00 |
| Indicator | HBM | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 62.35 |
| Support Level | $23.27 | $99.11 |
| Resistance Level | $26.40 | $193.87 |
| Average True Range (ATR) | 1.07 | 6.49 |
| MACD | 0.00 | 1.65 |
| Stochastic Oscillator | 86.23 | 83.93 |
Hudbay Minerals Inc is a copper-focused critical minerals company with three long-life operations and a pipeline of copper growth projects in Canada, Peru, and the United States. Its operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada), and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the company, which is complemented by gold, zinc, silver, and molybdenum production. Hudbay's growth pipeline includes the Copper World project and the Mason project in the USA, and the Llaguen project in Peru. The company's reportable segments are: Peru, which generates the maximum revenue, Manitoba, British Columbia, and Arizona. Geographically, it generates maximum revenue from China and Canada.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.